These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 8255684)
1. The physiologic effects of surfactant treatment on gas exchange in newborn premature infants with hyaline membrane disease. Cotton RB; Olsson T; Law AB; Parker RA; Lindstrom DP; Silberberg AR; Sundell HW; Sandberg K Pediatr Res; 1993 Oct; 34(4):495-501. PubMed ID: 8255684 [TBL] [Abstract][Full Text] [Related]
2. Lung mechanics and gas exchange in ventilated preterm infants during treatment of hyaline membrane disease with multiple doses of artificial surfactant (Exosurf). Pfenninger J; Aebi C; Bachmann D; Wagner BP Pediatr Pulmonol; 1992 Sep; 14(1):10-5. PubMed ID: 1437337 [TBL] [Abstract][Full Text] [Related]
3. Postnatal changes in pulmonary mechanics and energetics of infants with respiratory distress syndrome following surfactant treatment. Bhutani VK; Bowen FW; Sivieri EM Biol Neonate; 2005; 87(4):323-31. PubMed ID: 15985755 [TBL] [Abstract][Full Text] [Related]
4. Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: a pilot study. Sehgal SS; Ewing CK; Richards T; Taeusch HW J Natl Med Assoc; 1994 Jan; 86(1):46-52. PubMed ID: 8151722 [TBL] [Abstract][Full Text] [Related]
6. Comparative trial of artificial and natural surfactants in the treatment of respiratory distress syndrome of prematurity: experiences in a developing country. da Costa DE; Pai MG; Al Khusaiby SM Pediatr Pulmonol; 1999 May; 27(5):312-7. PubMed ID: 10344709 [TBL] [Abstract][Full Text] [Related]
7. Surfactant therapy for hyaline membrane disease: the Chandigarh experience. Narang A; Kumar P; Dutta S; Kumar R Indian Pediatr; 2001 Jun; 38(6):640-6. PubMed ID: 11418729 [No Abstract] [Full Text] [Related]
8. A controlled trial of synthetic surfactant in infants weighing 1250 g or more with respiratory distress syndrome. The American Exosurf Neonatal Study Group I, and the Canadian Exosurf Neonatal Study Group. Long W; Corbet A; Cotton R; Courtney S; McGuiness G; Walter D; Watts J; Smyth J; Bard H; Chernick V N Engl J Med; 1991 Dec; 325(24):1696-703. PubMed ID: 1944470 [TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy of exosurf and survanta surfactants on early clinical course of respiratory distress syndrome and complications of prematurity. Modanlou HD; Beharry K; Padilla G; Norris K; Safvati S; Aranda JV J Perinatol; 1997; 17(6):455-60. PubMed ID: 9447532 [TBL] [Abstract][Full Text] [Related]
10. Exosurf versus Survanta surfactant preparations: proportional-hazards regression analysis of time to successful extubation and discontinuation of oxygen therapy. Arnold C; Adams E; Torres E; Sidebottom R J Perinatol; 1996; 16(1):9-14. PubMed ID: 8869533 [TBL] [Abstract][Full Text] [Related]
11. Respiratory mechanics before and after late artificial surfactant rescue. Todd DA; Choukroun ML; Fayon M; Kays C; Guénard H; Galpérine I; Demarquez JL J Paediatr Child Health; 1995 Dec; 31(6):532-6. PubMed ID: 8924306 [TBL] [Abstract][Full Text] [Related]
12. Pulmonary mechanics in ventilated preterm infants with respiratory distress syndrome after exogenous surfactant administration: a comparison between two surfactant preparations. Choukroun ML; Llanas B; Apere H; Fayon M; Galperine RI; Guenard H; Demarquez JL Pediatr Pulmonol; 1994 Nov; 18(5):273-8. PubMed ID: 7898964 [TBL] [Abstract][Full Text] [Related]
14. Differences in immediate and short-term outcome of premature neonates treated with two types of exogenous surfactant preparation. Malathi I; Ng KC Ann Acad Med Singap; 1995 Nov; 24(6):781-4. PubMed ID: 8838980 [TBL] [Abstract][Full Text] [Related]
15. Static respiratory compliance in the newborn. III: Early changes after exogenous surfactant treatment. Stenson BJ; Glover RM; Parry GJ; Wilkie RA; Laing IA; Tarnow-Mordi WO Arch Dis Child Fetal Neonatal Ed; 1994 Jan; 70(1):F19-24. PubMed ID: 8117122 [TBL] [Abstract][Full Text] [Related]
16. Functional residual capacity and compliance of the respiratory system after surfactant treatment in premature infants with severe respiratory distress syndrome. Dinger J; Töpfer A; Schaller P; Schwarze R Eur J Pediatr; 2002 Sep; 161(9):485-90. PubMed ID: 12200607 [TBL] [Abstract][Full Text] [Related]
17. Changes in pulmonary artery pressure during the acute phase of respiratory distress syndrome treated with three different types of surfactant. Hamdan AH; Shaw NJ Pediatr Pulmonol; 1998 Mar; 25(3):191-5. PubMed ID: 9556011 [TBL] [Abstract][Full Text] [Related]
18. [The effect of surfactant therapy on the oxygen treatment of premature infants with HMD]. Iarŭkova N Akush Ginekol (Sofiia); 1998; 37(1):3-5. PubMed ID: 9770786 [TBL] [Abstract][Full Text] [Related]
19. Comparison of respiratory function and fluid balance in very low birthweight infants given artificial or natural surfactant or no surfactant treatment. Kavvadia V; Greenough A; Dimitriou G; Forsling M J Perinat Med; 1998; 26(6):469-74. PubMed ID: 10224604 [TBL] [Abstract][Full Text] [Related]
20. Surfactant therapy and high-frequency jet ventilation in the management of a piglet model of the meconium aspiration syndrome. Wiswell TE; Peabody SS; Davis JM; Slayter MV; Bent RC; Merritt TA Pediatr Res; 1994 Oct; 36(4):494-500. PubMed ID: 7816525 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]